Palliative Care Formulary
Palliative Care Formulary
Palliative Care Formulary
Formulary
2014 - 2017
This formulary for pain and symptom
management in adults is intended as a guide
for prescribers in hospital and community.
Management of Pain 1 - 4
Management of Symptoms 5 - 6
Pre-emptive prescribing 7
Syringe Drivers 8 - 9
Useful Contacts 11
Step 2
Non Opioid (Paracetamol 1g qds)
+ Weak Opioid (Codeine Phosphate 30-60mg qds
Or Tramadol 50-100mg qds)
+/- Adjuvants
Step 2:
Titration:
Paracetamol £ AND
Strong opioid to replace Step 2 weak opioid
Oral Morphine Solution £ (Oramorph ® 10mg/5ml): 2.5mg - 10mg every
4 hours plus PRN
(previous opioid use - see conversion chart)
Co-prescribe laxatives (see page 5) plus anti-emetic,
eg Haloperidol £ 0.5-1mg PRN
Maintenance:
Once pain stabilised on a regular 4 hourly Oral Morphine Solution,
calculate total dose given over previous 24 hours (regular plus PRN)
Administer in two divided doses as twice daily
Modified Release Morphine £ (e.g. Zomorph ®) .
Co-prescribe Oral Morphine Solution PRN of 1-4 hourly equivalent to
approximately 1/6th total daily dose of Modified Release Morphine.
ALTERNATIVE CHOICE/ROUTES
Oral:
Oxycodone ££ available as:
Immediate Release Oxycodone (OxyNorm® Liquid 5mg/5ml) and
Modified Release Oxycodone (OxyContin ®)
Transdermal:
1. Fentanyl ££
Fentanyl patches (each patch over 72 hrs)
Fentanyl is a potent opioid - a 25microgram/hr patch is equivalent to up to
90mg/day Oral Morphine
Fentanyl is not suitable for unstable pain and should NOT be used as a
1st line strong opioid. It is more likely to cause respiratory depression than
oral opioids.
Fentanyl is hepatically cleared. It is suitable for use in end stage renal
failure but may accumulate in hepatic failure and cause respiratory
depression
Seek specialist advice if the Fentanyl dose exceeds 75microgram/hr
3.
When converting to Fentanyl from:
30 - 60 12
60 - 90 25
90 - 135 37
135 - 180 50
180 - 225 62
225 - 315 75
2. Buprenorphine ££
Buprenorphine can be considered to be equipotent with Fentanyl
It is not renally cleared so is suitable for use in end stage renal failure
Buprenorphine may cause less Opioid Induced Hyperalgesia (OIH) than
other opioids (see page 5)
It is available in two formulations: BuTrans® 7 day patch or Transtec®
twice weekly patch
Buprenorphine is not suitable for unstable pain
BuTrans® may be useful for patients in the community who have been
using a weak opioid and are no longer able to swallow
Subcutaneous:
See section on syringe drivers on page 8
Alfentanil ££ may be useful for patients with renal impairment (eGFR <30)
for whom a patch is not suitable. Alfentanil has a short half-life so PRN
doses may need to be given every 30 minutes
ADJUVANT ANALGESICS:
Adjuvant analgesics are recommended at all 3 steps of the analgesic
ladder
Constipation:
Always co-prescribe a laxative (softener plus stimulant) - see page 5.
Sedative effect:
Expect a sedative effect for the first 2-3 days after starting opioids. If
this persists consider seeking specialist advice. Patients may require an
opioid switch, dose reduction or/and addition of an adjuvant. Specialists
may initiate Methylphenidate to counteract sedation.
Opioid toxicity:
This is commonly mild, and may include sedation, myoclonus and vague
hallucinations (patients report seeing ‘shadows on their shoulders’). May
respond to opioid switch/use of adjuvants. Seek specialist advice.
Confusion/delirium:
Exclude other possible causes before attributing to opioids. Seek advice.
Constipation:
Consider cause and non-drug management
Perform rectal examination
Macrogols and Lactulose are often poorly tolerated; patients rarely have
adequate additional fluid intake for these to be effective
Persistent constipation/impaction:
Rectal: Suppositories:
Bisacodyl £ 10mg -20mg od
Glycerin £ 1-2 od or
Enemas:
Sodium Citrate £ Micro-enema PRN
Phosphate enema ££ PRN
Oral: Macrogols (Laxido ®) ££ up to 8 sachets daily have been used
Colic:
Consider cause (for example constipation)
Hyoscine butylbromide £ SC 20mg 1-2 hrly PRN
or
Hyoscine butylbromide £ 60mg -120mg/24 hrs SC via syringe driver plus
20mg PRN 1-2 hrly
Agitation/terminal restlessness:
Consider reversible causes (for example hypercalcaemia, constipation,
urinary retention) and non-drug management
Oral:
Haloperidol 0.5-1mg prn 4 hourly
Lorazepam 0.5-1mg bd – tds (can be given via sublingual route)
Buccal:
Midazolam can be used under specialist advice
Subcutaneous:
Haloperidol 2.5mg stat or 5-10mg/24 hours in a driver
Levomepromazine 12.5mg stat or 12.5-50mg/24 hours in syringe driver
Midazolam 2.5mg stat or 10mg -30mg/24 hours in syringe driver
Higher doses of both drugs can be used under specialist advice.
Oral thrush:
Ensure good oral hygiene and denture care
Nystatin ££/Nystan ® £ 5mL qds
Miconazole £ gel 5 -10mL qds if end of life/unable to tolerate nystatin
Fluconazole ££ 50mg od for 7 days
Transdermal:
Hyoscine hydrobromide ££ patch 1mg/72 hours
Can cause confusion and drowsiness
7.
PALLIATIVE CARE EMERGENCIES
These are a guide for prescribing for patients not currently requiring
opioids or antiemetics. For other patients, please seek advice.
Haloperidol Cyclizine
Hyoscine butylbromide
Metoclopramide
Midazolam
Strong opioids
Levomepromazine Cyclizine
Hyoscine butylbromide
Metoclopramide
Midazolam
Strong opioids
Metoclopramide Haloperidol
Hyoscine butylbromide
Midazolam
Levomepromazine
Strong opioids
Midazolam Cyclizine
Hyoscine butylbromide
Haloperidol
Levomepromazine
Metoclopramide
Strong opioids
Syringe drivers and sites must be checked 4-hourly for irritation; once skin
is irritated absorption of drugs may be affected.
9.
CORE DRUG STOCKIST SCHEME
KEY
od - once daily
bd - twice daily
tds - three times daily
qds - four times daily
nocte - at night
PRN - as required
stat - immediately
hrly - hourly
IV - intravenous
SC - subcutaneous
PR - per rectum
10.
USEFUL CONTACTS
Barnsley Hospice:
01226 244244
Palcall:
Advice line
Call to be made by senior practitioner
01226 244244 (nights, weekends and bank holidays)
CONTRIBUTORS
This formulary was produced by a multidisciplinary working party with
representatives from primary and secondary care. The formulary will be
reviewed and updated on a regular basis.
BIBLIOGRAPHY
Back, I N 2001 – Palliative Medicine Handbook 3rd Edition – BPM Books,
Cardiff book.pallcare.info